Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
Clinical trial NCT04965064 · RECRUITING
Trial details
- NCT number
- NCT04965064
- Sponsor
- University of Rochester
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-23
- Primary completion
- 2026-09-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.